| Symbol | LTRN |
|---|---|
| Name | LANTERN PHARMA INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1920 MCKINNEY AVENUE,7TH FLOOR, DALLAS, Texas, 75201, United States |
| Telephone | +1 972 277-1136 |
| Fax | — |
| — | |
| Website | https://www.lanternpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001763950 |
| Description | Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firms pipeline of development programs involves four drug candidates and an Antibody Drug Conjugate (ADC) program directed towards eight therapeutic targets. Its A.I. platform, known as RADR, includes more than 18 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. Additional info from NASDAQ: |
(90% Positive) LANTERN PHARMA INC. (LTRN) Announces Enrollment Update for Deepens Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreLantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
Read moreLantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
Read moreLantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
Read moreNew Form SCHEDULE 13G/A - Lantern Pharma Inc. <b>Filed:</b> 2026-07-23 <b>AccNo:</b> 0001104659-26-086180 <b>Size:</b> 8 KB
Read moreLantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers
Read moreLantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
Read moreNew Form D - Lantern Pharma Inc. <b>Filed:</b> 2026-05-21 <b>AccNo:</b> 0001493152-26-024786 <b>Size:</b> 11 KB
Read moreLantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | Phase1 | Advanced Solid Tumor | Active_Not_Recruiting | 2023-06-09 | 2026-07-28 | ClinicalTrials.gov |
| NCT05456256 | A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advance… | Phase2 | Adenocarcinoma of Lung | Recruiting | 2023-03-01 | 2027-06-01 | ClinicalTrials.gov |
| NCT06132503 | Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients Wit… | Phase1 | Relapsed or Refractory Lymphomas | Recruiting | 2023-01-03 | 2028-11-30 | ClinicalTrials.gov |
| NCT03643107 | Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Resp… | Phase2 | Metastatic Castration-Resistant Prostate Cancer Patients | Completed | 2018-10-17 | 2022-08-01 | ClinicalTrials.gov |
| NCT00966914 | Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Re… | Phase3 | Non-small Cell Lung Cancer | Completed | 2010-04-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00039780 | Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast … | Phase3 | Breast Neoplasms | Completed | 2001-09-01 | 2014-09-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Carboplatin | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Pemetrexed | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-300 | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-284 | Other | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Nivolumab & Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-184 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Carboplatin | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Pemetrexed | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-300 | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-284 | Other | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Nivolumab & Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-184 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Carboplatin | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Pemetrexed | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-300 | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-284 | Other | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Nivolumab & Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-184 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-284 | Other | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Nivolumab & Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-184 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Carboplatin | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Pemetrexed | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-300 | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-284 | Other | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Nivolumab & Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-184 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-284 | Other | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Carboplatin | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Pemetrexed | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-300 | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Nivolumab & Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-184 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-284 | Other | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Carboplatin | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Pemetrexed | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-300 | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Nivolumab & Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-184 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-284 | Other | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Carboplatin | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Pemetrexed | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-300 | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Nivolumab & Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-184 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-284 | Other | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Carboplatin | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Pemetrexed | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-300 | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Nivolumab & Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| LP-184 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05933265 |
| Placebo in combination with cisplatin and docetaxel or paclitaxel | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT00966914 |
| Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel | Other | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT00966914 |
| Placebo | Other | Phase PHASE3 | Breast Neoplasms | COMPLETED | NCT00039780 |
| BNP7787 | Other | Phase PHASE3 | Breast Neoplasms | COMPLETED | NCT00039780 |
| Placebo | Other | Phase PHASE3 | Breast Neoplasms | COMPLETED | NCT00039780 |
| BNP7787 | Other | Phase PHASE3 | Breast Neoplasms | COMPLETED | NCT00039780 |
| Prednisolone 10 mg | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer Patients | COMPLETED | NCT03643107 |
| Irofulven | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer Patients | COMPLETED | NCT03643107 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05933265 |
| Spironolactone | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05933265 |
| LP-184 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05933265 |
| LP-284 | Other | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Carboplatin | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Pemetrexed | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-300 | Other | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Placebo in combination with cisplatin and docetaxel or paclitaxel | DRUG | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT00966914 |
| Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel | DRUG | Phase PHASE3 | Non-small Cell Lung Cancer | COMPLETED | NCT00966914 |
| Placebo | DRUG | Phase PHASE3 | Breast Neoplasms | COMPLETED | NCT00039780 |
| BNP7787 | DRUG | Phase PHASE3 | Breast Neoplasms | COMPLETED | NCT00039780 |
| LP-284 | DRUG | Phase PHASE1 | Relapsed or Refractory Lymphomas | RECRUITING | NCT06132503 |
| Olaparib | DRUG | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05933265 |
| Spironolactone | DRUG | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05933265 |
| LP-184 | DRUG | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05933265 |
| Carboplatin | DRUG | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Pemetrexed | DRUG | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| LP-300 | DRUG | Phase PHASE2 | Adenocarcinoma of Lung | RECRUITING | NCT05456256 |
| Irofulven | DRUG | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer Patients | COMPLETED | NCT03643107 |